immatics is a private biopharmaceutical company based in Tuebingen, Germany. We are focused on the discovery and development of innovative active immunotherapies against cancer. Our proprietary technology allows us to identify tumor-associated peptides (TUMAPs) that are associated with particular cancers.
http://www.immatics.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Monday
LOAD TIME
1.6 seconds
16x16
32x32
immatics biotechnologies GmbH
Niels●●●●●erich
Paul-Eh●●●●●●●Str. 15
Tue●●●gen , 72076
DE
View this contact
immatics biotechnologies GmbH
Niels Emmerich
Paul-Eh●●●●●●●Str. 15
Tue●●●gen , 72076
DE
View this contact
Cronon AG Professional IT-Services
Hostmaster Strato Rechenzentrum
Emmy-No●●●●●●●Str. 10
Kar●●●uhe , 76131
DE
View this contact
BUY YOUR DOMAIN
23
YEARS
9
MONTHS
29
DAYS
CRONON AG
WHOIS : whois.cronon.net
REFERRED : http://www.cronon.net
PAGES IN
THIS WEBSITE
2
SSL
EXTERNAL LINKS
93
SITE IP
134.119.101.3
LOAD TIME
1.64 sec
SCORE
6.2
Home - Immatics | immatics.com Reviews
https://immatics.com
immatics is a private biopharmaceutical company based in Tuebingen, Germany. We are focused on the discovery and development of innovative active immunotherapies against cancer. Our proprietary technology allows us to identify tumor-associated peptides (TUMAPs) that are associated with particular cancers.
immatics.com
Home | Immatics
http://immatics.com/index.php?PHPSESSID=63bebe60f6ebb9ad06aef84f2340746f
Immatics US, Inc. Adoptive Cellular Therapy (ACT). Adoptive Cellular Therapy (ACT). Careers – GmbH. Careers – U.S. Contact – GmbH. Contact – U.S. Immatics is a clinical-stage biopharmaceutical company dedicated to developing advanced immunotherapies that are active against cancer. Immatics is a leading cancer immunotherapy company and. Global leader in the discovery of novel targets for various types of cancer immunotherapies. In designing our immunotherapies we employ a unique and rational approach base...
Home | Immatics
http://immatics.com/index.php?page=91&modid2=2013&PHPSESSID=63bebe60f6ebb9ad06aef84f2340746f
Immatics US, Inc. Adoptive Cellular Therapy (ACT). Adoptive Cellular Therapy (ACT). Careers – GmbH. Careers – U.S. Contact – GmbH. Contact – U.S. Immatics is a clinical-stage biopharmaceutical company dedicated to developing advanced immunotherapies that are active against cancer. Immatics is a leading cancer immunotherapy company and. Global leader in the discovery of novel targets for various types of cancer immunotherapies. In designing our immunotherapies we employ a unique and rational approach base...
TOTAL PAGES IN THIS WEBSITE
2
Home | Immatics
http://www.immatics.de/index.php?page=91&modid2=2013&PHPSESSID=97c333b738bdf5feccb8fbf4045d67a2
Immatics US, Inc. Adoptive Cellular Therapy (ACT). Adoptive Cellular Therapy (ACT). Careers – GmbH. Careers – U.S. Contact – GmbH. Contact – U.S. Immatics is a clinical-stage biopharmaceutical company dedicated to developing advanced immunotherapies that are active against cancer. Immatics is a leading cancer immunotherapy company and. Global leader in the discovery of novel targets for various types of cancer immunotherapies. In designing our immunotherapies we employ a unique and rational approach base...
Partnerships - Scancell
http://www.scancell.co.uk/company/partnerships
8mg Higher Dose SCIB1 Study On Track. SCIB1 Granted FDA Orphan Drug Status. ImmunoBody technology used in prostate cancer protein discovery. DNA ImmunoBody Patent Granted in Japan. New data for SCIB1 in metastatic melanoma. Extension to Ichor Option and Issue of Equity. Investor update showcases Moditope platform and updates SCIB1 trial progress. DNA IB Patent in Australia. SCIB1 8mg Study Update. Scancell welcomes new study in The Journal of Clinical Investigation. ImmunoBody Patent Approved in US.
MIG Fonds: Portfolio A-Z
http://www.mig-fonds.de/index.php?id=396
Fonds 3 i. L. Fonds 1 i. L. Aktuelles Portfolio MIG Fonds von A-Z. APK Aluminium und Kunststoffe AG. BIOCRATES Life Sciences AG. Isarna Holding GmbH (vormals: Isarna Therapeutics). AdvanceCOR GmbH ist eine Biotechnologie-Firma, die innovative Medikamente zur Behandlung von Herz-Kreislauf-Erkrankungen entwickelt, mit Sitz in Martinsried bei München. Http:/ www.advancecor.de. AFFiRiS entwickelt Medikamente für bisher nicht behandelbare Krankheiten mit hohem therapeutischen Bedarf. Im Fokus stehen der M...
Activities at Tegernsee Conference 2009
http://www.tegernsee-conference.de/program/activities.htm
Diese Seite ist aus Gründen der Barrierefreiheit optimiert für aktuelle Browser. Sollten Sie einen älteren Browser verwenden, kann es zu Einschränkungen der Darstellung und Benutzbarkeit der Website kommen! The 3rd Tegernsee Conference at. July 2-4, 2009. Activities and the social program during the conference will be here in a short while. Please come back later. Dt Gesellschaft für Immuntherapie e.V.
Program of Tegernsee Conference 2009
http://www.tegernsee-conference.de/program/program2009.htm
Diese Seite ist aus Gründen der Barrierefreiheit optimiert für aktuelle Browser. Sollten Sie einen älteren Browser verwenden, kann es zu Einschränkungen der Darstellung und Benutzbarkeit der Website kommen! The 3rd Tegernsee Conference at. July 2-4, 2009. Thursday July 2, 2009. 430 PM Departure from Hotel Residence (by bus). 445 PM Arrival at La Villa - Aperitif. 515 530 Opening remarks. K-W Jauch, Munich. Using chemokines to direct leukocyte traffic and impact on cancer therapy. Friday July 3, 2009.
Abstractform - Tegernsee Conference 2009
http://www.tegernsee-conference.de/program/abstractform.htm
Diese Seite ist aus Gründen der Barrierefreiheit optimiert für aktuelle Browser. Sollten Sie einen älteren Browser verwenden, kann es zu Einschränkungen der Darstellung und Benutzbarkeit der Website kommen! The 3rd Tegernsee Conference at. July 2-4, 2009. You may submit an abstract for poster presentation. The best poster will be awarded with. The Asklepios Poster Prize 2009 for innovative cancer therapy. Submitting an abstract for the 3. Guideline for abstract submission:.
Bestehende Partnerschaften | MorphoSys AG
https://www.morphosys.de/partnerschaften/bestehende-partnerschaften
MorphoSys auf einen Blick. Engineering the Medicines of Tomorrow. Discovery, Alliances and Technologies. Kompetent in der Arzneimittelentwicklung. Herstellung, Chemie- und Produktionskontrolle. Investition in die Medikamente von morgen. Im Folgenden sind die Abkommen der MorphoSys AG kurz beschrieben, die spürbare finanzielle Auswirkungen gehabt haben bzw. in zukünftigen Geschäftsjahren haben könnten (in alphabetischer Reihenfolge). MorphoSys und Astellas Pharma. Wurde Ende 2007 eingestellt. Es befin...
Hepavac – Cancer Vaccine development for Hepatocellular Carcinoma – Partner 5 – IMM (Vice-Coordinator)
http://www.hepavac.eu/consortium/partner-5-imm-vice-coordinator
Cancer Vaccine development for Hepatocellular Carcinoma - LOGIN. Partner 1 INT (Coordinator). Partner 5 IMM (Vice-Coordinator). Data Safety Monitoring Board. Patient and Clinical Site Representative. Hepavac in the news. Partner 5 IMM (Vice-Coordinator). Artner 5 IMM (Vice-Coordinator). Brief description of the organization. Partner 1 INT (Coordinator). Partner 5 IMM (Vice-Coordinator). 2013-2016 Cancer Vaccine development for Hepatocellular Carcinoma.
www.step-award.de: Gewinner 2007
http://www2.step-award.de/Gewinner-2007.18.0.html
STEP Award - Projekte and Veranstaltungen - FAZ.NET Willkommen. Direkt zum Hauptmenü. Die Nanogate AG wurde zum Gesamtsieger des STEP Award 2007 gekürt. In der Kategorie Markt und Kunde siegte die Retina Implant AG. Die immatics biotechnologies GmbH wurde Sieger in der Kategorie Prozesse. Das biopharmazeutische Unternehmen mit Sitz in Tübingen konzentriert sich auf die Entwicklung neuer Immun-therapeutika zur Krebsbehandlung. Die Produktkandidaten von immatics basieren auf tumor-assoziierten Peptiden...
TOTAL LINKS TO THIS WEBSITE
93
ImmAtheOwN - DeviantArt
Window.devicePixelRatio*screen.width 'x' window.devicePixelRatio*screen.height) :(screen.width 'x' screen.height) ; this.removeAttribute('onclick')" class="mi". Window.devicePixelRatio*screen.width 'x' window.devicePixelRatio*screen.height) :(screen.width 'x' screen.height) ; this.removeAttribute('onclick')". Join DeviantArt for FREE. Forgot Password or Username? Deviant for 7 Years. This deviant's full pageview. Last Visit: 252 weeks ago. This is the place where you can personalize your profile! 1048;&#...
imma.being | Pain & Performance Solutions
Pain and Performance Solutions. Transform & Transcend. 100% Guarantee of a Healing Experience – To Be Listened To and To Upgrade Function. Dedicated to helping you upgrade through an evidence-based practice, drawing from ancient wisdom, to elevate human potential, consciousness, and health. In all sessions Michael facilitates change and your personal evolution using education, touch, movement and acupuncture therapy, providing you the power to fully express your mind, body, and spirit in this life. Culti...
Blog de immathias - Immathias vous présente : ^^ les MARSEILLER ^^ - Skyrock.com
Mot de passe :. J'ai oublié mon mot de passe. Immathias vous présente : les MARSEILLER. Voilla comme promis je reparle de marseille. Mise à jour :. L'Olympique de Marseille s. Ecoute Skyrock en live. Les n 1 sont Rap and RnB. Abonne-toi à mon blog! L'Olympique de Marseille souhaite à tous ses supporters une belle et heureuse année 2010! Que lit-on sur la page qui se tourne? Est-il utile de préciser que rien n'est perdu? Inscrire une nouvelle ligne au palmarès en 2010? Ce serait la délicieuse cerise sur l...
immatics biotechnologies - active against cancer
Is a clinical-stage biopharmaceutical company dedicated to developing advanced immunotherapies that are active against cancer. Our goal is to spearhead a new era in the treatment of cancer by enabling patients to live significantly longer and better lives than with today’s therapies. Immatics biotechnologies receives $20m grant from the State of Texas for the development of immunotherapies against cancer. Immaticsâ contribution to validation of tumour mutations by mass spectrometry published in Nature.
immatics biotechnologies - active against cancer
Is a clinical-stage biopharmaceutical company dedicated to developing advanced immunotherapies that are active against cancer. Our goal is to spearhead a new era in the treatment of cancer by enabling patients to live significantly longer and better lives than with today’s therapies. Immatics biotechnologies receives $20m grant from the State of Texas for the development of immunotherapies against cancer. Immaticsâ contribution to validation of tumour mutations by mass spectrometry published in Nature.
Home - Immatics
Bringing the Power of T cells to Cancer Patients. Proprietary and Partnered Immune-oncology Programs. World Class Team and Science. Go to Bispecific TCR Molecules. Immatics has developed three innovative approaches to producing Adoptive Cell Therapies (ACT): ACTolog. These therapies are directed against targets which will transform the current landscape of tumor therapy. Bispecific T-Cell Receptor Molecules. About Bispecific T-Cell receptor molecules. MorphoSys and Immatics Biotechnologies Enter Strategi...
immatics biotechnologies - active against cancer
Is a clinical-stage biopharmaceutical company dedicated to developing advanced immunotherapies that are active against cancer. Our goal is to spearhead a new era in the treatment of cancer by enabling patients to live significantly longer and better lives than with today’s therapies. Immatics biotechnologies receives $20m grant from the State of Texas for the development of immunotherapies against cancer. Immaticsâ contribution to validation of tumour mutations by mass spectrometry published in Nature.
immatics biotechnologies - active against cancer
Is a clinical-stage biopharmaceutical company dedicated to developing advanced immunotherapies that are active against cancer. Our goal is to spearhead a new era in the treatment of cancer by enabling patients to live significantly longer and better lives than with today’s therapies. Immatics biotechnologies receives $20m grant from the State of Texas for the development of immunotherapies against cancer. Immaticsâ contribution to validation of tumour mutations by mass spectrometry published in Nature.
Home - Immatics
Bringing the Power of T cells to Cancer Patients. Proprietary and Partnered Immune-oncology Programs. World Class Team and Science. Go to Bispecific TCR Molecules. Immatics has developed three innovative approaches to producing Adoptive Cell Therapies (ACT): ACTolog. These therapies are directed against targets which will transform the current landscape of tumor therapy. Bispecific T-Cell Receptor Molecules. About Bispecific T-Cell receptor molecules. MorphoSys and Immatics Biotechnologies Enter Strategi...
immatics biotechnologies - active against cancer
Is a clinical-stage biopharmaceutical company dedicated to developing advanced immunotherapies that are active against cancer. Our goal is to spearhead a new era in the treatment of cancer by enabling patients to live significantly longer and better lives than with today’s therapies. Immatics biotechnologies receives $20m grant from the State of Texas for the development of immunotherapies against cancer. Immaticsâ contribution to validation of tumour mutations by mass spectrometry published in Nature.
immatics biotechnologies - active against cancer
Is a clinical-stage biopharmaceutical company dedicated to developing advanced immunotherapies that are active against cancer. Our goal is to spearhead a new era in the treatment of cancer by enabling patients to live significantly longer and better lives than with today’s therapies. Immatics biotechnologies receives $20m grant from the State of Texas for the development of immunotherapies against cancer. Immaticsâ contribution to validation of tumour mutations by mass spectrometry published in Nature.
SOCIAL ENGAGEMENT